PLYMOUTH MEETING, November 5, 2026 — Inovio’s first FDA approval for Voceryq, a DNA medicine targeting a rare throat disease, marks a pivotal moment for the biotech. The $460,000 treatment cost and upcoming confirmatory trials will test its commercial viability.
The Bottom Line: Revenue Starts, But Cash Runway Is Tight
Inovio’s Voceryq, priced at $460,000 for a four-dose series, gives the company its first product revenue after 40 years. But investors will note the figure that matters: cash lasts into early 2027, per CEO Jacqueline Shea. Q3 earnings on November 10 will reveal more about the launch plans and financial health.
By the Numbers: Stock Surge, But Still Below $2
Shares jumped 214% to $1.89 post-approval, yet trade below $2. HC Wainwright’s $5 price target looks ambitious. The market cap sits at $171.64 million, reflecting cautious optimism. Voceryq’s 27% surgical-free response rate in 26 patients is promising, but the confirmatory trial is make-or-break for continued approval.
Pipeline Potential: Beyond Throat Disease
Voceryq’s success validates Inovio’s DNA platform. The pipeline includes VGX-3100 for cervical dysplasia and INO-5410 for cancer. These candidates could expand revenue streams if approved, though they remain in earlier stages. The company’s $80.4 million legal win in October provides a financial buffer, but commercialization costs loom large.
Inovio’s first approval is a milestone, but the path to profitability is steep. Retail investors should watch the confirmatory trial, Q3 earnings, and insurance coverage decisions closely. The figure that matters most? How many patients—and insurers—will pay $460,000 for Voceryq.
Sources
- Plymouth Meeting Biotech Inovio Wins FDA Nod for What It Calls the First DNA Medicine
- Inovio Pharmaceuticals
- US FDA approves Inovio's treatment for rare throat disease; shares surge
- INO Stock Price and Chart — NASDAQ:INO — TradingView
- FDA Grants Accelerated Approval to INOVIO’s Voceryq for RRP, Reducing Surgical Burden | PharmExec
- INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
Photo: Jphkim (CC0)
